首页> 外文期刊>Annals of tropical medicine and parasitology >The chemotherapy of rodent malaria. LXII. Drug combinations to impede the selection of drug resistance, part 5: rates of development of resistance to some inhibitors of folate metabolism and to artesunate.
【24h】

The chemotherapy of rodent malaria. LXII. Drug combinations to impede the selection of drug resistance, part 5: rates of development of resistance to some inhibitors of folate metabolism and to artesunate.

机译:灭鼠疟疾的化学疗法。 LXII。阻碍抗药性选择的药物组合,第5部分:对某些叶酸代谢抑制剂和青蒿琥酯抗药性的发展速度。

获取原文
获取原文并翻译 | 示例
           

摘要

In recent years infection with chloroquine-resistant Plasmodium falciparum has been combatted with two long-acting antimalarials, pyrimethamine and sulfadoxine, in the combination known as Fansidar that exerts a strong, synergistic action on the asexual stages of the parasite. This second-line regimen, however, is failing increasingly because of the selection of resistant clones in endemic areas, and effective, safe, alternative drugs or drug combinations that are also affordable are urgently needed. Antimalarial drugs with shorter half-lives than those of pyrimethamine or sulfadoxine are likely to be slower to select resistant parasites. In the experiments reported here, the baseline in-vivo responses of rodent malarial parasites to chlorproguanil and proguanil and their active metabolites, chlorcycloguanil and cycloguanil, as well as those to dapsone and artesunate, were explored. In general, the most sensitive parasite to all of these compounds was P. chabaudi. When the drugs were used, individually, to select resistance via the '2%-relapse technique', relatively stable resistance to each was obtained in P. chabaudi as well as in P. berghei and P. yoelii ssp. NS, the last of these being also highly resistant to chloroquine. Of most concern was the rapidity and high level of resistance developed by P. chabaudi to artesunate. The experiments also validated the use of chlorcycloguanil or cycloguanil as surrogates for chlorproguanil or proguanil. Further studies to investigate the possible value of administering chlorproguanil-dapsone, with or without artesunate, are under way and will be reported separately.
机译:近年来,抗氯喹恶性疟原虫的感染已通过两种长效抗疟药,乙胺嘧啶和磺胺多辛进行了抗药性,这种组合称为Fansidar,对寄生虫的无性阶段发挥强大的协同作用。然而,由于在流行地区选择了抗性克隆,因此这种第二线方案越来越失败,因此迫切需要有效,安全,替代药物或负担得起的药物组合。半衰期比乙胺嘧啶或磺胺多辛的半衰期短的抗疟药可能在选择抗药性寄生虫方面较慢。在此处报道的实验中,研究了啮齿动物疟疾寄生虫对氯丙胍和丙胍及其活性代谢产物氯环胍和环胍以及对氨苯砜和青蒿琥酯的基线体内反应。通常,对所有这些化合物最敏感的寄生虫是沙巴氏假单胞菌。当单独使用这些药物以通过“ 2%复发技术”选择抗药性时,在chabaudi假单胞菌,伯氏疟原虫和yoelii假单胞菌中均获得相对稳定的耐药性。 NS,它们中的最后一个对氯喹也有很高的抵抗力。最令人关注的是沙巴氏菌对青蒿琥酯产生的快速性和高水平的抵抗力。实验还验证了使用氯环鸟嘌呤或环鸟嘌呤作为氯丙胍或氯胍的替代物。目前正在进行进一步的研究,以调查在有或没有青蒿琥酯的情况下服用氯丙胍-氨苯砜的可能价值,并将另行报告。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号